Tegafur,Gimeracil and Oteracil Potassium

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal Cancer

Phase 2

Completed

Conditions: Gastric Cancer

Interventions: Drug: S-1
Drug: Oxaliplatin
Drug: Trastuzumab
Drug: Docetaxel

First Posted Date: 2016-04-01

Last Posted Date: 2022-08-17

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 180

Registration Number: NCT02725424

Locations: 🇨🇳
Chinese Academy of Medical Sciences, Beijing, Beijing, China

S-1 and Radiotherapy for Elderly Esophageal Cancer Patients

Phase 2

Withdrawn

Conditions: Esophageal Cancer
S-1
Radiotherapy

Interventions: Drug: S-1
Radiation: radiotherapy

First Posted Date: 2016-03-23

Last Posted Date: 2023-09-22

Lead Sponsor: Zhejiang Provincial People's Hospital

Registration Number: NCT02716688

Locations: 🇨🇳
Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China

Radiofrequency Ablation Combined With S-1 for Pancreatic Cancer With Liver Metastasis

Phase 2

Conditions: Carcinoma, Pancreatic

Interventions: Procedure: radiofrequency ablation
Drug: S-1

First Posted Date: 2015-12-18

Last Posted Date: 2015-12-18

Lead Sponsor: Fudan University

Target Recruit Count: 30

Registration Number: NCT02634502

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Cancer.

Phase 2

Completed

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Radiation: SMART
Drug: DDP
Drug: S-1

First Posted Date: 2015-11-17

Last Posted Date: 2020-09-04

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 42

Registration Number: NCT02606916

Locations: 🇨🇳
Sun yat-sen University Cancer Center, Guangzhou, Guangdong, China

Endobiliary Radiofrequency Ablation With S-1 for Unresectable Cholangiocarcinoma

Not Applicable

Completed

Conditions: Cholangiocarcinoma

Interventions: Device: radiofrequency ablation
Drug: S-1
Device: Stent

First Posted Date: 2015-10-30

Last Posted Date: 2019-11-19

Lead Sponsor: First People's Hospital of Hangzhou

Target Recruit Count: 66

Registration Number: NCT02592538

Locations: 🇨🇳
Hangzhou First People's Hospital, Hangzhou, Zhejiang, China

Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction

Phase 1

Completed

Conditions: Adenocarcinoma,Stomach
Adenocarcinoma, Esophagogastric Junction

Interventions: Drug: S-1

First Posted Date: 2015-09-30

Last Posted Date: 2021-04-29

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 30

Registration Number: NCT02564367

Locations: 🇩🇪
Klinikum der Universität München, Campus Großhadern, München, Bayern, Germany

A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Phase 2

Completed

Conditions: Metastatic Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: Ramucirumab
Drug: Placebo
Drug: S-1
Drug: Oxaliplatin
Drug: Paclitaxel

First Posted Date: 2015-09-02

Last Posted Date: 2022-03-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 191

Registration Number: NCT02539225

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Toyonaka, Japan
🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy